A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa
Linaclotide, a synthetic guanylyl cyclase C (GC‐C) agonist, and the prostone analog,
Lubiprostone, are approved to manage chronic idiopathic constipation and constipation …
Lubiprostone, are approved to manage chronic idiopathic constipation and constipation …
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome
V Andresen, M Camilleri, IA Busciglio, A Grudell… - Gastroenterology, 2007 - Elsevier
Background & Aims: Oral linaclotide, a novel agonist of guanylate cylase-C, stimulates
intestinal fluid secretion and transit, and decreases visceral hypersensitivity in animal …
intestinal fluid secretion and transit, and decreases visceral hypersensitivity in animal …
Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome
R Sood, AC Ford - Therapeutic advances in chronic disease, 2013 - journals.sagepub.com
Chronic idiopathic constipation (CIC) and irritable bowel syndrome (IBS) are functional
disorders of the lower gastrointestinal tract. Their prevalence in the general population is …
disorders of the lower gastrointestinal tract. Their prevalence in the general population is …
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation
MV Roque, M Camilleri - Expert review of gastroenterology & …, 2011 - Taylor & Francis
Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are two
functional gastrointestinal disorders that are associated with constipation. CC and IBS-C …
functional gastrointestinal disorders that are associated with constipation. CC and IBS-C …
Pilot study on the effect of linaclotide in patients with chronic constipation
JM Johnston, CB Kurtz, DA Drossman… - Official journal of the …, 2009 - journals.lww.com
OBJECTIVES: Chronic constipation is a common gastrointestinal disorder with limited
treatment options. Oral administration of linaclotide, a novel peptide agonist of guanylate …
treatment options. Oral administration of linaclotide, a novel peptide agonist of guanylate …
Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation
Background Linaclotide is efficacious in the management of irritable bowel syndrome with
constipation (IBS‐C), yet relatively little is known regarding its effect on human …
constipation (IBS‐C), yet relatively little is known regarding its effect on human …
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit
RW Busby, AP Bryant, WP Bartolini, EA Cordero… - European journal of …, 2010 - Elsevier
Linaclotide is a first-in-class, orally administered 14-amino acid peptide that is in
development for the treatment of irritable bowel syndrome with constipation and chronic …
development for the treatment of irritable bowel syndrome with constipation and chronic …
Linaclotide for the management of irritable bowel syndrome with constipation
P Layer, V Stanghellini - Alimentary pharmacology & …, 2014 - Wiley Online Library
Background Irritable bowel syndrome with constipation (IBS‐C) represents a significant
burden to patients and healthcare systems due to its prevalence and lack of successful …
burden to patients and healthcare systems due to its prevalence and lack of successful …
Efficacy of linaclotide for patients with chronic constipation
AJ Lembo, CB Kurtz, JE MacDougall, BJ Lavins… - Gastroenterology, 2010 - Elsevier
BACKGROUND & AIMS: Linaclotide is a minimally absorbed peptide agonist of the
guanylate cyclase-C receptor that stimulates intestinal fluid secretion and transit and …
guanylate cyclase-C receptor that stimulates intestinal fluid secretion and transit and …
[HTML][HTML] Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation
RH Thomas, K Allmond - Pharmacy and Therapeutics, 2013 - ncbi.nlm.nih.gov
155 mal systemic absorption following oral administration. It is resistant to degradation by
stomach acid and trypsin, pepsin, aminopeptidase, and chymotrypsin; however, it produces …
stomach acid and trypsin, pepsin, aminopeptidase, and chymotrypsin; however, it produces …